The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?

Metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as one of the most difficult challenges in modern medicine. With global obesity and type 2 diabetes continuing to rise, fatty liver disease has become a worldwide health burden. The reclassification of non-alcoholic fatty liver disease into MASLD reflects this link, but the critical bottleneck remains fibrosis, the scarring of liver tissue that predicts long-term outcomes. For years, weight-loss therapies such as GLP-1 agonists have dominated the conversation. Yet while these drugs have transformed the obesity market, they have delivered only modest and inconsistent improvements in fibrosis. A new generation of anti-fibrotic drugs is now being positioned to fill this gap, raising the question: can they finally succeed where weight-loss therapies fall short?

Why have weight-loss therapies delivered metabolic improvements but struggled on fibrosis outcomes?

Weight-loss therapies, particularly GLP-1 receptor agonists such as semaglutide, have demonstrated an ability to reduce liver fat and resolve steatohepatitis in a significant proportion of patients. In late-stage studies, semaglutide produced histologic improvements in steatohepatitis resolution and notable reductions in hepatic fat. However, its effect on fibrosis—the strongest predictor of mortality and morbidity in liver disease—was limited. For many patients, even substantial weight loss did not translate into meaningful fibrosis regression, particularly in those with advanced disease.

This gap underscores why fibrosis is a crucial endpoint. While metabolic control can reduce fat accumulation and inflammation, fibrosis represents long-term structural damage to the liver. Unless therapies can halt or reverse fibrosis, the risk of progression to cirrhosis, transplantation, or liver failure remains high. Regulators and payers increasingly require evidence of fibrosis regression as the gold standard for approval and reimbursement. In this context, weight-loss drugs are necessary but insufficient.

Why is fibrosis the most important clinical marker, and why are regulators demanding more evidence?

Among all histologic features of MASH, fibrosis is the strongest predictor of outcomes, including liver-related mortality. Patients with fibrosis stage F3 or F4 are at greatest risk of progressing to cirrhosis, liver decompensation, and hepatocellular carcinoma. For this reason, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have centered their guidance on endpoints that measure fibrosis improvement. Regulators have also become more cautious after years of trial failures in the field, demanding hard data rather than surrogate markers.

Payers, too, are skeptical of therapies that primarily reduce steatohepatitis or fat without robust evidence of fibrosis benefit. From a cost-effectiveness standpoint, preventing progression to cirrhosis or avoiding transplant is far more valuable than managing fat alone. As a result, drug developers that cannot demonstrate fibrosis benefit face an uphill battle in achieving widespread adoption, regardless of weight-loss efficacy.

Which anti-fibrotic drugs are showing promise in the MASH pipeline, and how do they differ from weight-loss agents?

The most advanced anti-fibrotic candidates are designed to act directly on fibrosis pathways while also addressing inflammation and metabolic dysfunction. Lanifibranor, a pan-PPAR agonist, has shown dose-dependent improvements in both steatohepatitis and fibrosis in Phase 2 trials. Patients achieved significant resolution of MASH and at least one stage of fibrosis improvement, leading to optimism around its ongoing Phase 3 study.

Another strong contender is efruxifermin, an FGF21 analog that has demonstrated reductions in hepatic fat and histologic improvements in fibrosis. Data suggest potential in both pre-cirrhotic and compensated cirrhosis populations, which is particularly important as most patients present at advanced stages of disease. Roche’s recent acquisition of 89bio for $3.5 billion underscores industry confidence in this class, with its lead FGF21 analog pegozafermin being positioned as a potential backbone therapy in combination regimens.

These drugs differ from GLP-1s in mechanism and intent. While GLP-1s primarily reduce caloric intake and improve insulin sensitivity, anti-fibrotic drugs directly target liver remodeling and fibrogenesis. This distinction could make them indispensable in advanced disease, where metabolic improvements alone are insufficient.

What limitations continue to hinder weight-loss therapies in advanced liver disease patients?

GLP-1s and other incretin-based drugs offer compelling metabolic and weight-loss benefits, but their impact diminishes in advanced fibrosis. In F3 and F4 patients, structural scarring is less amenable to reversal, and weight loss does not always translate into histologic improvement. Moreover, tolerability remains an issue. Gastrointestinal side effects lead to discontinuation in a notable percentage of patients, undermining long-term adherence.

Durability is another concern. Many patients experience weight regain if treatment is interrupted, and fibrosis often returns once therapy stops. The cost of chronic use is also significant. GLP-1 drugs remain expensive, and access is uneven across healthcare systems. For late-stage patients, these limitations highlight the need for complementary therapies that can act directly on fibrosis.

What challenges do anti-fibrotic drug developers face in achieving regulatory and commercial success?

Despite promising signals, anti-fibrotic drug development faces steep challenges. Attrition rates from Phase 2 to Phase 3 remain high, reflecting the difficulty of demonstrating consistent fibrosis improvement in diverse patient populations. Trial design is complex, requiring invasive biopsies and long timelines to measure histologic change. Regulators are demanding increasingly stringent endpoints, such as one-stage fibrosis improvement without worsening of MASH or transplant-free survival metrics.

Commercialization will also depend on payer acceptance. Insurers will demand cost-effectiveness, real-world safety data, and proof of long-term benefit before approving widespread coverage. With potential patient populations numbering in the millions, healthcare systems will weigh affordability heavily. Without a compelling health-economic case, even drugs that achieve approval may struggle with uptake.

Are combination regimens the future of liver disease treatment, and how would they work in practice?

The emerging consensus is that no single therapy will dominate the MASH market. Combination regimens are expected to define the next generation of care. In this model, GLP-1s or other incretins provide metabolic control and weight loss, while anti-fibrotic agents such as FGF21 analogs or pan-PPARs address fibrosis directly.

This dual approach mirrors strategies in other chronic diseases, such as oncology and HIV, where multi-agent therapy has become the standard. The combination of metabolic and anti-fibrotic effects could maximize efficacy, expand the eligible patient population, and provide durable benefits. Clinical trials are already exploring these regimens, and payers may be more willing to support therapies that reduce both metabolic and structural liver risk simultaneously.

What do recent trial results suggest about the realistic potential for fibrosis regression?

Recent data suggest that fibrosis regression is possible but challenging. Semaglutide showed that more than one-third of patients achieved fibrosis improvement without worsening of MASH, a meaningful step but not a transformative one. By contrast, lanifibranor and efruxifermin have delivered stronger signals, particularly in F2 and F3 populations. Importantly, efruxifermin demonstrated benefits even in compensated cirrhosis, where treatment options are scarce.

These results indicate that fibrosis regression is no longer a theoretical goal. With the right mechanisms and patient selection, significant improvements are achievable. The next two to three years, as Phase 3 readouts arrive, will be critical in determining whether these early signals translate into clinical practice.

How are investors and analysts interpreting the future of anti-fibrotic drug development in the MASH sector?

Investor sentiment toward the MASH sector has shifted from skepticism to cautious optimism. For years, failed trials left analysts wary, but recent results have revived interest. Roche’s move into 89bio is seen as a validation of FGF21 analogs, while other big pharma players are watching closely for opportunities to expand portfolios.

From an institutional flow perspective, biotech funds are increasing exposure to mid-cap players with strong Phase 2 or Phase 3 data, reflecting confidence in future M&A. However, risks remain high. Many investors are treating anti-fibrotic milestones probabilistically, discounting long-dated commercial assumptions heavily. Retail investors should remain aware that while breakthroughs are possible, setbacks have been frequent in this field.